Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
Phase of Trial: Phase III
Latest Information Update: 15 Oct 2015
Price : $35 *
At a glance
- Drugs Peptide hydrolase inhibitors (Primary) ; Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 11 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.